Although many of these inhibitors have been evaluated in clinical trials like MLN-518, a novel type III receptor tyrosine kinases inhibitor designed to treat AML in combination with other chemotherapeutic drugs 19, 20; few FLT3 inhibitors have been approved for monotherapy, such as AC220. Here, FLT3 is linked to acute myeloid leukemia.